Alexander Baraniskin1, Barbara Buchberger2, Christian Pox3, Ulli Graeven4, Julian W Holch5, Wolff Schmiegel6, Volker Heinemann5. 1. Department of Medicine, Knappschaftskrankenhaus, Ruhr-University of Bochum, Germany. Electronic address: Alexander.Baraniskin@rub.de. 2. University of Duisburg-Essen, Faculty of Economics and Business Administration, Institute for Health Care Management and Research, Essen, Germany. 3. St. Joseph-Stift Bremen, Medizinische Klinik, Bremen, Germany. 4. Department of Medicine I, Hospital Maria Hilf, Mönchengladbach, Germany. 5. Department of Internal Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Munich, Germany. 6. Department of Medicine, Knappschaftskrankenhaus, Ruhr-University of Bochum, Germany.
Abstract
BACKGROUND: This systematic review and meta-analysis aims to evaluate the additive effect of bevacizumab when combined with first-line chemotherapy in metastatic colorectal cancer (mCRC). METHODS: We searched EMBASE, MEDLINE, the Cochrane Library in April 2018. When possible, data were pooled to estimate summary effects. The present analysis evaluated treatment related efficacy based on progression-free survival (PFS) and overall survival (OS). The analysis was performed to define the overall effect and the effect observed in currently used chemotherapy regimens. RESULTS: Seven randomised studies were included. In the analysis of the overall effect, PFS (hazard ratio [HR] 0.71, p < 0.00001) and OS (HR 0.85, p = 0.0008) clearly favoured bevacizumab plus chemotherapy versus chemotherapy alone. When the analysis was focused on currently used chemotherapy excluding 5-FU bolus regimens and including only infusional 5-FU plus irinotecan or oxaliplatin, the addition of bevacizumab prolonged PFS (HR 0.79, p < 0.0001) but not OS (HR 0.92, p = 0.18). However, addition of bevacizumab to fluoropyrimidine monotherapy lead to a significant prolongation of PFS (HR 0.57, p < 0.00001) and OS (HR 0.83, p = 0.03). CONCLUSION: The present meta-analysis demonstrates that the effect of bevacizumab on survival is not consistent throughout the included regimens. Considering only presently used regimens, a significant effect on PFS and OS was only observed when bevacizumab was added to fluoropyrimidine monotherapy.
BACKGROUND: This systematic review and meta-analysis aims to evaluate the additive effect of bevacizumab when combined with first-line chemotherapy in metastatic colorectal cancer (mCRC). METHODS: We searched EMBASE, MEDLINE, the Cochrane Library in April 2018. When possible, data were pooled to estimate summary effects. The present analysis evaluated treatment related efficacy based on progression-free survival (PFS) and overall survival (OS). The analysis was performed to define the overall effect and the effect observed in currently used chemotherapy regimens. RESULTS: Seven randomised studies were included. In the analysis of the overall effect, PFS (hazard ratio [HR] 0.71, p < 0.00001) and OS (HR 0.85, p = 0.0008) clearly favoured bevacizumab plus chemotherapy versus chemotherapy alone. When the analysis was focused on currently used chemotherapy excluding 5-FU bolus regimens and including only infusional 5-FU plus irinotecan or oxaliplatin, the addition of bevacizumab prolonged PFS (HR 0.79, p < 0.0001) but not OS (HR 0.92, p = 0.18). However, addition of bevacizumab to fluoropyrimidine monotherapy lead to a significant prolongation of PFS (HR 0.57, p < 0.00001) and OS (HR 0.83, p = 0.03). CONCLUSION: The present meta-analysis demonstrates that the effect of bevacizumab on survival is not consistent throughout the included regimens. Considering only presently used regimens, a significant effect on PFS and OS was only observed when bevacizumab was added to fluoropyrimidine monotherapy.
Authors: Arndt Stahler; Volker Heinemann; Ingrid Ricard; Jobst C von Einem; Clemens Giessen-Jung; Christoph Benedikt Westphalen; Marlies Michl; Kathrin Heinrich; Lisa Miller-Phillips; Ivan Jelas; Sebastian Stintzing; Dominik Paul Modest Journal: J Cancer Res Clin Oncol Date: 2020-06-19 Impact factor: 4.553
Authors: Yasmin Kamal; Dennis Dwan; Hannah J Hoehn; Rebeca Sanz-Pamplona; M Henar Alonso; Victor Moreno; Chao Cheng; Michael J Schell; Youngchul Kim; Seth I Felder; Hedy S Rennert; Marilena Melas; Charalampos Lazaris; Joseph D Bonner; Erin M Siegel; David Shibata; Gad Rennert; Stephen B Gruber; H Robert Frost; Christopher I Amos; Stephanie L Schmit Journal: Oncoimmunology Date: 2021-03-09 Impact factor: 8.110
Authors: Erik van Dijk; Erik van Werkhoven; Rebecca Asher; Jennifer K Mooi; David Espinoza; Hendrik F van Essen; Harm van Tinteren; Nicole C T van Grieken; Cornelis J A Punt; Niall C Tebbutt; Bauke Ylstra Journal: Int J Cancer Date: 2022-05-23 Impact factor: 7.316